{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'b.', 'Evidence of current clinically significant uncontrolled arrhythmias,', 'including clinically significant ECG abnormalities such as 2nd degree', '(Type II) or 3rd degree atrioventricular (AV) block.', 'c.', 'History of myocardial infarction, acute coronary syndromes (including', 'unstable angina), coronary angioplasty, or stenting or bypass grafting within', 'six months of Screening.', 'd.', 'Class III or IV heart failure as defined by the New York Heart Association', 'functional classification system [NYHA, 1994]', 'e.', 'Uncontrolled hypertension', '14. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs', 'chemically related to GSK2857916, or any of the components of the study', 'treatment.', '15. Pregnant or lactating female.', '16. Active infection requiring antibiotic, antiviral, or antifungal treatment.', '17. Known HIV infection.', '18. Presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody', '(HBcAb at screening or within 3 months prior to first dose of study treatment', '19. Positive hepatitis C antibody test result or positive hepatitis C RNA test result at', 'screening or within 3 months prior to first dose of study treatment.', 'Note: Participants with positive Hepatitis C antibody due to prior resolved', 'disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is', 'obtained.', 'Note: Hepatitis RNA testing is optional and participants with negative Hepatitis', 'C antibody test are not required to also undergo Hepatitis C RNA testing.', '6.3.', 'Lifestyle Restrictions', 'Contact lenses are prohibited while the participant is on study.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently enrolled. A minimal set of screen failure information is required', 'to ensure transparent reporting of screen failure participants to meet the Consolidated', 'Standards of Reporting Trials (CONSORT) publishing requirements and to respond to', 'queries from regulatory authorities. Minimal information to be entered into INFORM', 'includes demography, screen failure details, eligibility criteria, and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may be rescreened. Rescreened participants must be assigned a new unique participant', 'number that is different from the initial number.', '55']['2017N330177_04', 'CONFIDENTIAL', '205678', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment intended to be administered to', 'a study participant according to the study protocol. GSK2857916 will be administered', 'intravenously.', 'GSK2857916 will be administered intravenously, at the study sites, as either 2.5 mg/kg or', '3.4 mg/kg calculated dose.', 'Product name:', 'GSK2857916', 'Frozen liquid, 30 mg/vial solution in single-use vial', 'or', 'Dosage form:', 'Lyophilized powder, 100 mg/vial in single-use vial for reconstitution', '(independent cohort with approximately 25 participants)', '30 mg/vial / 2.5 or 3.4 mg/kg (Frozen liquid)', 'Unit dose strength(s)/Dose Level(s):', 'or', '100 mg/vial / 2.5 or 3.4 mg/kg (Lyophilized powder)', 'Route of Administration', 'Delivered as IV solution over at least 30 minutes*.', 'Dilute GSK2857916 in normal 0.9% saline to the appropriate concentration for', 'the dose. Doses of GSK2857916 are to be administered as an IV infusion via', \"an infusion pump. See Investigator's Brochure for compatible administration\", 'Dosing instructions:', 'materials.', 'For lyophilized powder only: Reconstitute GSK2857916 lyophilized powder 100', 'mg/vial 2.0mL of water for injection (WFI); dilute with saline before use.', 'Manufacturer/ Source of', 'GSK/Baxter', 'Procurement:', '*Infusions may be prolonged in the event of an infusion reaction. If multiple participants experience clinically significant', 'infusion reactions, the infusion rate may be slowed for all future administrations of study treatment(s) for all', 'participants. Should this global change in infusion rate be required, it will be communicated to the sites in writing.', '7.1.', 'GSK2857916 Treatments Administered', 'GSK2857916 is to be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an', 'IV infusion, via an infusion pump. Administration of GSK2857916 will be documented', 'in the clinic source documents and reported in the electronic case report form (eCRF).', 'The time of start and end of infusion will be documented in eCRF.', 'GSK2857916 will be administered on Day 1 of each cycle. Premedication is not required', 'prior to infusion unless deemed medically necessary by the investigator, in which case it', 'should be administered according to institutional recommendations.', 'Any participant experiencing an IRR must receive appropriate medical treatment. When', \"the participant's condition is stable, the infusion may be restarted at a slower rate. For\", 'details on restarting the GSK2857916 infusion after interruption for IRR, please see', 'Table 11.', 'In general, upon restarting, the infusion rate must be decreased by half at the time the', 'infusion was interrupted.', 'Participants will be treated until disease progression, until unacceptable toxicity, or until', 'confirmed CR (Section 8).', '56']\n\n###\n\n", "completion": "END"}